Perrigo Company plc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-0.7%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
$2.19next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
Monitoring Framework
Key Performance Indicators
All In Adjusted Diluted EPS Quarterly0.4Target: $2.00 to $2.30
Core Adjusted EPS Quarterly0.4Target: $2.25 to $2.55
All In Net Sales Growth Quarterly-720.0%Target: -5.5% to -1.5%
Core Net Sales Growth Quarterly-830.0%Target: -3.0% to +1.0%
Watch Items
- Permanent CEO AppointmentTrigger: Board selection of a permanent successor to Interim CEO Albert A. ManzoneAction: Assess strategic alignment and potential shifts in the 'Three-S' plan execution.
- Infant Formula Strategic ReviewTrigger: Announcement of divestiture, joint venture, or restructuring of the nutrition segmentAction: Re-evaluate long-term margin expansion targets and capital allocation priorities.
- Operational Enhancement Program SavingsTrigger: Achievement of $80 million to $100 million in annual run-rate cost savings by the end of 2026Action: Monitor quarterly operating margin expansion to verify cost-out execution.
Research as of 20 Jun 2026